30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q14 Revenue: RTI Surgical

$50.5MM, +22%

  • Spine $20.4MM, +16%
  • Bone Graft Substitutes/General Orthopaedic $9.2MM, +20%
  • Sports Medicine $11.3MM, +19%
  • Ortho Fixation $9.4MM, +41%


  • Growth drivers include strong growth of U.S. direct sales, Streamline OCT, surgeon engagement efforts and investments in instrument sets


map3 Allograft Update:

  • In early 4Q, received FDA letter addressing certain language on map3 website and technical aspects of allograft processing
  • Submitted comprehensive data package to address comments, provide certification of technical components, demonstrate that there is no cell expansion process
  • Expected next steps include conversations with FDA, face-to-face meeting, possibly in 4Q
  • Notes that map3 is was not planned to be a significant product in 2014 or 2015